Viking Therapeutics, Inc. (NASDAQ:VKTX):
Viking Therapeutics to Report Financial Results for Third Quarter 2017 on November 8, 2017.
The company is trading up by 2.15% since yesterday’s close of $2.38.
Viking Therapeutics, Inc., launched on October 24, 2012, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Business’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). The Business’s second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. VK2809 belongs to a family of prodrugs, which are cleaved in vivo to release potent thyromimetics. The Company is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). X-ALD is an X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. The disease is caused by mutations in a peroxisomal transporter of very long chain fatty acids (VLCFA), known as the adenosine triphosphate binding cassette transporter D1, or ABCD1..
It is trading at $2.38 which is quite a bit higher than the 50 day moving average which is $1.97 and significantly higher than the 200 day moving average of $1.95. The 50 day moving average went up $0.41 or +20.76% and the 200 day average was up $0.43.
As of the latest earnings report the EPS was $-0.83 and is estimated to be $-0.83 for the current year with 27,697,000 shares outstanding. Analysts expect next quarter’s EPS to be $-0.18 and the next full year EPS is projected to be $-0.80.
Investors are a little more bearish on the company recently as inferred by the motion in short interest. The company had a rise in short interest of 214.17% as of October 13, 2017 from the last reporting period. Short interest grew from 319,148 to 1,002,683 over that period. The short-interest ratio decreased to 1.0 and the percentage of shorted shares is 0.04% as of October 13.